Incidence, patient characteristics and treatment patterns of early-stage triple-negative breast cancer (TNBC) in Bulgaria: A retrospective analysis based on real-world data
Pharmacia,
Год журнала:
2025,
Номер
72, С. 1 - 6
Опубликована: Март 24, 2025
Breast
cancer
(BC)
is
the
third
most
common
cancer,
making
up
10.8%
of
cases
in
both
men
and
women.
In
Bulgaria,
it
has
highest
rates
diagnosis
(23.3%)
death
among
women,
with
around
3558
new
each
year,
5–7%
which
are
attributed
to
triple-negative
breast
(TNBC).
This
lower
than
global
rate
12–15%.
The
current
3-year
non-interventional
study
aims
analyse
newly
diagnosed
patients
a
focus
on
treatment
patterns
neo-adjuvant
adjuvant
settings
measure
time
spent
(real-world
treatment,
rwTOT)
using
secondary
real-world
data
collected
for
other
purposes.
For
observed
period,
TNBC
accounted
5.2%
all
diagnoses,
peak
ages
ranging
from
45
65
60
70,
suggesting
later-age
diagnosis.
Real-world
show
tendency
endocrine
(letrozole,
goserelin
tamoxifen)
targeted
therapy
(trastuzumab,
pertuzumab/trastuzumab
bevacizumab)
еTNBC
(early
stage
TNBC)
patients,
not
fully
compliant
guidelines
but
suggests
possible
presence
so-called
immunophenotypic
BC
very
low
expression
levels
ER/PR
(<
10–20%).
average
rWToT
years
approximately
3.60
months
3.6
neoadjuvant
therapy.
Язык: Английский
Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects
Frontiers in Molecular Biosciences,
Год журнала:
2025,
Номер
12
Опубликована: Апрель 14, 2025
Breast
cancer
(BC)
remains
a
complex
and
widespread
problem,
affecting
millions
of
women
worldwide,
Among
the
various
subtypes
BC,
triple-negative
breast
(TNBC)
is
particularly
challenging,
representing
approximately
20%
all
BC
cases,
survival
rate
TNBC
patients
generally
worse
than
other
BC.
heterogeneous
disease
characterized
by
lack
expression
three
receptors:
estrogen
(ER),
progesterone
(PR),
human
epidermal
growth
factor
receptor
2
(HER2),
resulting
conventional
hormonal
therapies
are
ineffective
for
its
management.
Despite
therapeutic
approaches
have
been
explored,
but
no
definitive
solution
has
found
yet
TNBC.
Current
treatments
options
chemotherapy,
immunotherapy,
radiotherapy
surgery,
although,
these
some
limitations,
such
as
development
resistance
to
anti-cancer
drugs,
off-target
toxicity,
which
remain
primary
obstacles
significant
challenges
Several
findings
shown
that
EVs
exhibit
promise
in
many
diseases,
similar
important
role
observed
types
tumor.
Studies
suggest
may
offer
potential
management
This
review
highlights
multifaceted
roles
TNBC,
emphasizing
their
involvement
progression,
diagnosis
approach,
well
biomarkers
drug
delivery.
Язык: Английский
Radiologic imaging biomarkers in triple-negative breast cancer: a literature review about the role of artificial intelligence and the way forward
Deleted Journal,
Год журнала:
2024,
Номер
1(1)
Опубликована: Янв. 1, 2024
Abstract
Breast
cancer
is
one
of
the
most
common
and
deadly
cancers
in
women.
Triple-negative
breast
(TNBC)
accounts
for
approximately
10%-15%
diagnoses
an
aggressive
molecular
subtype
associated
with
important
challenges
its
diagnosis,
treatment,
prognostication.
This
poses
urgent
need
developing
more
effective
personalized
imaging
biomarkers
TNBC.
Towards
this
direction,
artificial
intelligence
(AI)
radiologic
holds
a
prominent
role,
leveraging
unique
advantages
images,
being
used
routinely
TNBC
staging,
treatment
planning,
offering
high-resolution
whole-tumour
visualization,
combined
immense
potential
AI
to
elucidate
anatomical
functional
properties
tumours
that
may
not
be
easily
perceived
by
human
eye.
In
review,
we
synthesize
current
state-of-the-art
applications
assisting
Our
goal
provide
comprehensive
overview
radiomic
deep
learning-based
developments
their
impact
on
advancing
management
over
last
decade
(2013-2024).
For
completeness
start
brief
introduction
AI,
radiomics,
learning.
Next,
focus
clinically
relevant
AI-based
diagnostic,
predictive,
prognostic
models
images
evaluated
We
conclude
opportunities
future
directions
towards
response
predictions,
evaluations
Язык: Английский
Potential Therapeutic Targets in Triple‐Negative Breast Cancer Based on Gene Regulatory Network Analysis: A Comprehensive Systems Biology Approach
International Journal of Breast Cancer,
Год журнала:
2024,
Номер
2024(1)
Опубликована: Янв. 1, 2024
Background:
Triple‐negative
breast
cancer
(TNBC)
is
an
aggressive
subtype
with
limited
treatment
options.
This
study
aimed
at
identifying
potential
therapeutic
targets
in
TNBC
using
gene
regulatory
network
analysis
and
a
system
biology
approach.
Methods
:
The
GSE38959
dataset
was
reanalyzed
to
identify
differentially
expressed
genes
(DEGs)
tissues
compared
normal
samples.
Protein–protein
interaction
networks
were
constructed,
hub
identified.
Survival
performed
GEPIA2.
Gene
built
upstream
regulators.
Cross‐platform
verification
conducted
independent
RNA‐seq
(GSE58135).
Expression
of
prognostic
markers
versus
non‐TNBC
samples
bc‐GenExMiner.
Results:
A
total
943
DEGs
identified
tissues.
CHEK1
PLK1
as
central
genes,
overexpression
correlating
poor
prognosis.
GABPB1
the
most
influential
regulator
through
analysis,
while
JUN
exhibited
interactions
among
302
consistently
modulated
confirmed
cross‐platform
verification.
validated
by
expression
analysis.
Conclusion
provides
insights
into
molecular
mechanisms
suggests
CHEK1,
PLK1,
their
regulators
for
treatment.
Язык: Английский